Yahoo
NasdaqCM - Nasdaq Real Time Price USD

CervoMed Inc. (CRVO)

1.4300 +0.0100 (+0.70%)
At close: November 9 at 4:00:01 PM EST
1.4300 0.0000 (0.00%)
After hours: November 9 at 5:34:42 PM EST
Chart Range Bar
Loading chart for CRVO
Chart does not reflect overnight price.
  • Previous Close 1.4200
  • Open 1.3900
  • Bid 1.6400 x 200
  • Ask 1.6900 x 1000
  • Day's Range 1.3401 - 1.4500
  • 52 Week Range 1.2700 - 10.0000
  • Volume 314,379
  • Avg. Volume 291,037
  • Market Cap (intraday) 21.62M
  • Beta (5Y Monthly) -3.99
  • PE Ratio (TTM) --
  • EPS (TTM) -3.3000
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 15.00
  • Zacks Rating Neutral

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

www.cervomed.com

15

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CRVO
81.90%
S&P 500 (^GSPC)
10.29%

1-Year Return

CRVO
79.34%
S&P 500 (^GSPC)
12.20%

3-Year Return

CRVO
85.60%
S&P 500 (^GSPC)
73.67%

5-Year Return

CRVO
95.76%
S&P 500 (^GSPC)
61.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -5.9M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-8M
-6M
-4M
-2M
0
-80000.0%
-60000.0%
-40000.0%
-20000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

7.00
15.00 Average
1.4300 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/5/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 25 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -70.33%

  • Return on Equity (ttm)

    -131.52%

  • Revenue (ttm)

    8.73k

  • Net Income Avi to Common (ttm)

    -28.52M

  • Diluted EPS (ttm)

    -3.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.6M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -15.99M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: